

## DAFTAR PUSTAKA

- Abad, E., Graifer, D., dan Lyakhovich, A., 2020. DNA damage response and resistance of cancer stem cells. *Cancer Letters*, **474**: 106–117.
- Ahmed, A., Shamsi, A., Mohammad, T., Hasan, G.M., Islam, A., dan Hassan, M.I., 2021. Aurora B kinase: a potential drug target for cancer therapy. *Journal of Cancer Research and Clinical Oncology*, **147**: 2187–2198.
- Al-Hajj, M. dan Clarke, M.F., 2004. Self-renewal and solid tumor stem cells. *Oncogene*, **23**: 7274–7282.
- Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., dan Clarke, M.F., 2003. Prospective identification of tumorigenic breast cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **100**: 3983–3988.
- Arora, S., Singh, S., Piazza, G.A., Contreras, C.M., Panyam, J., dan Singh, A.P., 2012. Honokiol: a novel natural agent for cancer prevention and therapy. *Current Molecular Medicine*, **12**: 1244–1252.
- Avtanski, D.B., Nagalingam, A., Bonner, M.Y., Arbiser, J.L., Saxena, N.K., dan Sharma, D., 2014. Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis. *Molecular Oncology*, **8**: 565–580.
- Bayat, A., 2002. Bioinformatics. *BMJ: British Medical Journal*, **324**: 1018–1022.
- Bertran-Alamillo, J., Cattani, V., Schoumacher, M., Codony-Servat, J., Giménez-Capitán, A., Cantero, F., dkk., 2019. AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. *Nature Communications*, **10**: 1812.
- Brabletz, T., Kalluri, R., Nieto, M.A., dan Weinberg, R.A., 2018. EMT in cancer. *Nature Reviews Cancer*, **18**: 128–134.
- Butti, R., Gunasekaran, V.P., Kumar, T.V.S., Banerjee, P., dan Kundu, G.C., 2019. Breast cancer stem cells: Biology and therapeutic implications. *The International Journal of Biochemistry & Cell Biology*, **107**: 38–52.
- Caslini, C., Hong, S., Ban, Y.J., Chen, X.S., dan Ince, T.A., 2019. HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells. *Oncogene*, **38**: 6599–6614.
- Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., dkk., 2012. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discovery*, **2**: 401–404.
- Chin, C.-H., Chen, S.-H., Wu, H.-H., Ho, C.-W., Ko, M.-T., dan Lin, C.-Y., 2014. cytoHubba: identifying hub objects and sub-networks from complex interactome. *BMC Systems Biology*, **8**: S11.
- Comşa, Ş., Cîmpean, A.M., dan Raica, M., 2015. The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. *Anticancer Research*, **35**: 3147–3154.
- Crane, C., Panner, A., Pieper, R.O., Arbiser, J., dan Parsa, A.T., 2009. Honokiol mediated inhibition of PI3K/mTOR pathway: A potential strategy to overcome immunoresistance in glioma, breast and prostate carcinoma

- without impacting T cell function. *Journal of immunotherapy (Hagerstown, Md. : 1997)*, **32**: 585–592.
- Cui, W., Wang, Y., Chen, Q., Sun, W., Cai, L., Tan, Y., dkk., 2013. Magnolia extract (BL153) ameliorates kidney damage in a high fat diet-induced obesity mouse model. *Oxidative Medicine and Cellular Longevity*, **2013**: 367040.
- De Angelis, M.L., Francescangeli, F., dan Zeuner, A., 2019. Breast Cancer Stem Cells as Drivers of Tumor Chemoresistance, Dormancy and Relapse: New Challenges and Therapeutic Opportunities. *Cancers*, **11**: 1569.
- de Beça, F.F., Caetano, P., Gerhard, R., Alvarenga, C.A., Gomes, M., Paredes, J., dkk., 2013. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. *Journal of Clinical Pathology*, **66**: 187–191.
- Dunaway, L.S. dan Pollock, J.S., 2021. HDAC1: an environmental sensor regulating endothelial function. *Cardiovascular Research*, **118**: 1885–1903.
- Drápela, S., Bouchal, J., Jolly, M.K., Culig, Z., dan Souček, K., 2020. ZEB1: A Critical Regulator of Cell Plasticity, DNA Damage Response, and Therapy Resistance. *Frontiers in Molecular Biosciences*, **7**: .
- Eliasz, I. dan Weil, E., 2020. Intravenous Honokiol in Drug-Resistant Cancer: Two Case Reports. *Integrative Cancer Therapies*, **19**: 1534735420922615.
- Elmore, S., 2007. Apoptosis: A Review of Programmed Cell Death. *Toxicologic pathology*, **35**: 495–516.
- Fillmore, C.M. dan Kuperwasser, C., 2008. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. *Breast Cancer Research*, **10**: R25.
- Fink, S.L. dan Cookson, B.T., 2005. Apoptosis, Pyroptosis, and Necrosis: Mechanistic Description of Dead and Dying Eukaryotic Cells. *Infection and Immunity*, **73**: 1907–1916.
- Gfeller, D., Grosdidier, A., Wirth, M., Daina, A., Michielin, O., dan Zoete, V., 2014. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. *Nucleic Acids Research*, **42**: W32–W38.
- H., F., Zarghi, A., Kobarfard, F., Zendehdel, R., Nakhjavani, M., Arfaiee, S., dkk., 2011. Remarks in Successful Cellular Investigations for Fighting Breast Cancer Using Novel Synthetic Compounds, dalam: Gunduz, M. (Editor), *Breast Cancer - Focusing Tumor Microenvironment, Stem Cells and Metastasis*. InTech.
- Halling-Brown, M.D., Bulusu, K.C., Patel, M., Tym, J.E., dan Al-Lazikani, B., 2012. canSAR: an integrated cancer public translational research and drug discovery resource. *Nucleic Acids Research*, **40**: D947–D956.
- Herberg, S., Simeone, A., Oikawa, M., Jullien, J., Bradshaw, C.R., Teperek, M., dkk., 2015. Histone H3 lysine 9 trimethylation is required for suppressing the expression of an embryonically activated retrotransposon in *Xenopus laevis*. *Scientific Reports*, **5**: 14236.
- Hermawan, A., Ikawati, M., Jenie, R.I., Khumaira, A., Putri, H., Nurhayati, I.P., dkk., 2021a. Identification of potential therapeutic target of naringenin in

- breast cancer stem cells inhibition by bioinformatics and in vitro studies. *Saudi Pharmaceutical Journal*, **29**: 12–26.
- Hermawan, A., Ikawati, M., Khumaira, A., Putri, H., Jenie, R.I., Angraini, S. meta, dkk., 2020. Bioinformatics and In Vitro Studies Reveal the Importance of p53, PPAR $\gamma$  and Notch Signaling Pathway in Inhibition of Breast Cancer Stem Cells by Hesperetin. *Advanced Pharmaceutical Bulletin*, .
- Hermawan, A., Khumaira, A., Ikawati, M., Putri, H., Jenie, R.I., Angraini, S.M., dkk., 2021b. Identification of key genes of hesperidin in inhibition of breast cancer stem cells by functional network analysis. *Computational Biology and Chemistry*, **90**: 107427.
- Hermawan, A., Putri, H., Hanif, N., Fatimah, N., dan Prasetyo, H.H., 2022. Identification of potential target genes of honokiol in overcoming breast cancer resistance to tamoxifen. *Frontiers in Oncology*, **12**: .
- Huang, D.W., Sherman, B.T., dan Lempicki, R.A., 2009. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Research*, **37**: 1–13.
- Huang, K.-J., Kuo, C.-H., Chen, S.-H., Lin, C.-Y., dan Lee, Y.-R., 2018. Honokiol inhibits in vitro and in vivo growth of oral squamous cell carcinoma through induction of apoptosis, cell cycle arrest and autophagy. *Journal of Cellular and Molecular Medicine*, **22**: 1894–1908.
- Huang, R., Langdon, S.P., Tse, M., Mullen, P., Um, I.H., Faratian, D., dkk., 2015. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer. *Oncotarget*, **7**: 4695–4711.
- Ji, X., Lu, Y., Tian, H., Meng, X., Wei, M., dan Cho, W.C., 2019. Chemoresistance mechanisms of breast cancer and their countermeasures. *Biomedicine & Pharmacotherapy*, **114**: 108800.
- Jiang, C., Liu, J., Guo, M., Gao, X., Wu, X., Bai, N., dkk., 2020. The NAD-dependent deacetylase SIRT2 regulates T cell differentiation involved in tumor immune response. *International Journal of Biological Sciences*, **16**: 3075–3084.
- Kadam, C.Y. dan Abhang, S.A., 2016. Apoptosis Markers in Breast Cancer Therapy, dalam: *Advances in Clinical Chemistry*. Elsevier, hal. 143–193.
- Keiser, M.J., Setola, V., Irwin, J.J., Laggner, C., Abbas, A., Hufeisen, S.J., dkk., 2009. Predicting new molecular targets for known drugs. *Nature*, **462**: 175–181.
- Kerr, J.F.R., Wyllie, A.H., dan Currie, A.R., 1972. Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics. *British Journal of Cancer*, **26**: 239–257.
- Khan, S., Suryavanshi, M., Kaur, J., Nayak, D., Khurana, A., Manchanda, R.K., dkk., 2021. Stem cell therapy: A paradigm shift in breast cancer treatment. *World Journal of Stem Cells*, **13**: 841–860.
- Kuhn, M., von Mering, C., Campillos, M., Jensen, L.J., dan Bork, P., 2008. STITCH: interaction networks of chemicals and proteins. *Nucleic Acids Research*, **36**: D684–D688.
- Law, A.M.K., Rodriguez de la Fuente, L., Grundy, T.J., Fang, G., Valdes-Mora, F., dan Gallego-Ortega, D., 2021. Advancements in 3D Cell Culture

- Systems for Personalizing Anti-Cancer Therapies. *Frontiers in Oncology*, **11**: .
- Lee, J.S., Sul, J.Y., Park, J.B., Lee, M.S., Cha, E.Y., dan Ko, Y.B., 2019. Honokiol induces apoptosis and suppresses migration and invasion of ovarian carcinoma cells via AMPK/mTOR signaling pathway. *International Journal of Molecular Medicine*, **43**: 1969–1978.
- Lindau, D., Gielen, P., Kroesen, M., Wesseling, P., dan Adema, G.J., 2013. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. *Immunology*, **138**: 105–115.
- Liu, H., Zang, C., Emde, A., Planas-Silva, M.D., Rosche, M., Kühnl, A., dkk., 2008. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. *European Journal of Pharmacology*, **591**: 43–51.
- Lo, Y.C., Teng, C.M., Chen, C.F., Chen, C.C., dan Hong, C.Y., 1994. Magnolol and honokiol isolated from *Magnolia officinalis* protect rat heart mitochondria against lipid peroxidation. *Biochemical Pharmacology*, **47**: 549–553.
- Lv, D., Hu, Z., Lu, L., Lu, H., dan Xu, X., 2017. Three-dimensional cell culture: A powerful tool in tumor research and drug discovery. *Oncology Letters*, **14**: 6999–7010.
- Maiti, S. dan Picard, D., 2022. Cytosolic Hsp90 Isoform-Specific Functions and Clinical Significance. *Biomolecules*, **12**: 1166.
- Malumbres, M. dan Barbacid, M., 2001. To cycle or not to cycle: a critical decision in cancer. *Nature Reviews Cancer*, **1**: 222–231.
- Miller, K.D., Nogueira, L., Mariotto, A.B., Rowland, J.H., Yabroff, K.R., Alfano, C.M., dkk., 2019. Cancer treatment and survivorship statistics, 2019. *CA: A Cancer Journal for Clinicians*, **69**: 363–385.
- Motz, G.T., Santoro, S.P., Wang, L.-P., Garrabrant, T., Lastra, R.R., Hagemann, I.S., dkk., 2014. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. *Nature Medicine*, **20**: 607–615.
- Muguruma, M., Teraoka, S., Miyahara, K., Ueda, A., Asaoka, M., Okazaki, M., dkk., 2020. Differences in drug sensitivity between two-dimensional and three-dimensional culture systems in triple-negative breast cancer cell lines. *Biochemical and Biophysical Research Communications*, **533**: 268–274.
- Musgrove, E.A., Caldon, C.E., Barraclough, J., Stone, A., dan Sutherland, R.L., 2011. Cyclin D as a therapeutic target in cancer. *Nature Reviews Cancer*, **11**: 558–572.
- Nguyen, M. dan Osipo, C., 2022. Targeting Breast Cancer Stem Cells Using Naturally Occurring Phytoestrogens. *International Journal of Molecular Sciences*, **23**: 6813.
- Nounou, M.I., ElAmrawy, F., Ahmed, N., Abdelraouf, K., Goda, S., dan Syed-Sha-Qhattal, H., 2015. Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. *Breast Cancer : Basic and Clinical Research*, **9**: 17–34.

- Nugoli, M., Chuchana, P., Vendrell, J., Orsetti, B., Ursule, L., Nguyen, C., dkk., 2003. Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications. *BMC Cancer*, **3**: 13.
- Olivares-Urbano, M.A., Griñán-Lisón, C., Marchal, J.A., dan Núñez, M.I., 2020. CSC Radioresistance: A Therapeutic Challenge to Improve Radiotherapy Effectiveness in Cancer. *Cells*, **9**: 1651.
- Olsson, A.-K., Dimberg, A., Kreuger, J., dan Claesson-Welsh, L., 2006. VEGF receptor signalling? in control of vascular function. *Nature Reviews Molecular Cell Biology*, **7**: 359–371.
- Ong, C.P., Lee, W.L., Tang, Y.Q., dan Yap, W.H., 2020. Honokiol: A Review of Its Anticancer Potential and Mechanisms. *Cancers*, **12**: 48.
- Park, E.-J., Min, H.-Y., Chung, H.-J., Hong, J.-Y., Kang, Y.-J., Hung, T.M., dkk., 2009. Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells. *Cancer Letters*, **277**: 133–140.
- Pelengaris, S., Khan, M., dan Evan, G., 2002. c-myc: more than just a matter of life and death. *Nature Reviews Cancer*, **2**: 764.
- Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., dkk., 2000. Molecular portraits of human breast tumours. *Nature*, **406**: 747–752.
- Perrot-Applanat, M. dan Di Benedetto, M., 2012. Autocrine functions of VEGF in breast tumor cells. *Cell Adhesion & Migration*, **6**: 547–553.
- Pestell, T.G., Jiao, X., Kumar, M., Peck, A.R., Prisco, M., Deng, S., dkk., 2017. Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. *Oncotarget*, **8**: 81754–81775.
- Poivre, M. dan Duez, P., 2017. Biological activity and toxicity of the Chinese herb *Magnolia officinalis* Rehder & E. Wilson (Houpo) and its constituents. *Journal of Zhejiang University. Science. B*, **18**: 194–214.
- Ponti, D., Costa, A., Zaffaroni, N., Pratesi, G., Petrangolini, G., Coradini, D., dkk., 2005. Isolation and In vitro Propagation of Tumorigenic Breast Cancer Cells with Stem/Progenitor Cell Properties. *Cancer Research*, **65**: 5506–5511.
- Rajendran, V. dan Jain, M.V., 2018. In Vitro Tumorigenic Assay: Colony Forming Assay for Cancer Stem Cells, dalam: Papaccio, G. dan Desiderio, V. (Editor), *Cancer Stem Cells: Methods and Protocols, Methods in Molecular Biology*. Springer, New York, NY, hal. 89–95.
- Rao, X., Huang, X., Zhou, Z., dan Lin, X., 2013. An improvement of the  $2^{-\Delta\Delta CT}$  method for quantitative real-time polymerase chain reaction data analysis. *Biostatistics, bioinformatics and biomathematics*, **3**: 71–85.
- Roche, J., 2018. The Epithelial-to-Mesenchymal Transition in Cancer. *Cancers*, **10**: 52.
- Sajjadi, S.E., Ghanadian, M., Haghighi, M., dan Mouhebat, L., n.d. Cytotoxic effect of *Cousinia verbascifolia* Bunge against OVCAR-3 and HT-29 cancer cells. *Journal of Herbmed Pharmacology*, **4**: 15–19.
- Santolla, M.F. dan Maggiolini, M., 2020. The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives. *Cancers*, **12**: 3029.



- Sengupta, S., Nagalingam, A., Muniraj, N., Bonner, M.Y., Mistriotis, P., Afthinos, A., dkk., 2017. Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3. *Oncogene*, **36**: 5709–5721.
- Shan, N.L., Wahler, J., Lee, H.J., Bak, M.J., Gupta, S.D., Maehr, H., dkk., 2017. Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer. *The Journal of Steroid Biochemistry and Molecular Biology*, , 19th Vitamin D Workshop **173**: 122–129.
- Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., dkk., 2003. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Research*, **13**: 2498–2504.
- Singh, T., Prasad, R., dan Katiyar, S.K., 2013. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo. *Epigenetics*, **8**: 54–65.
- Solomon, H., Dinowitz, N., Pateras, I.S., Cooks, T., Shetzer, Y., Molchadsky, A., dkk., 2018. Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers. *Oncogene*, **37**: 1669–1684.
- Soule, H.D., Vazquez, J., Long, A., Albert, S., dan Brennan, M., 1973. A Human Cell Line From a Pleural Effusion Derived From a Breast Carcinoma 2. *JNCI: Journal of the National Cancer Institute*, **51**: 1409–1416.
- Stecklein, S.R., Kumaraswamy, E., Behbod, F., Wang, W., Chaguturu, V., Harlan-Williams, L.M., dkk., 2012. BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation. *Proceedings of the National Academy of Sciences*, **109**: 13650–13655.
- Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., dkk., 2015. STRING v10: protein-protein interaction networks, integrated over the tree of life. *Nucleic Acids Research*, **43**: D447–452.
- Tang, A., Gao, K., Chu, L., Zhang, R., Yang, J., dan Zheng, J., 2017. Aurora kinases: novel therapy targets in cancers. *Oncotarget*, **8**: 23937–23954.
- Tang, Z., Ding, S., Huang, H., Luo, P., Qing, B., Zhang, S., dkk., 2017. HDAC1 triggers the proliferation and migration of breast cancer cells via upregulation of interleukin-8. *Biological Chemistry*, **398**: 1347–1356.
- Teng, S.-C., Chen, Y.-Y., Su, Y.-N., Chou, P.-C., Chiang, Y.-C., Tseng, S.-F., dkk., 2004. Direct Activation of HSP90A Transcription by c-Myc Contributes to c-Myc-induced Transformation \*. *Journal of Biological Chemistry*, **279**: 14649–14655.
- Tian, W., Deng, Y., Li, L., He, H., Sun, J., dan Xu, D., 2013. Honokiol synergizes chemotherapy drugs in multidrug resistant breast cancer cells via enhanced apoptosis and additional programmed necrotic death. *International Journal of Oncology*, **42**: 721–732.
- Toss, A. dan Cristofanilli, M., 2015. Molecular characterization and targeted therapeutic approaches in breast cancer. *Breast cancer research: BCR*, **17**: 60.

- Vavilala, D.T., O'Bryhim, B.E., Ponnaluri, V.K.C., White, R.S., Radel, J., Symons, R.C.A., dkk., 2013. Honokiol inhibits pathological retinal neovascularization in oxygen-induced retinopathy mouse model. *Biochemical and Biophysical Research Communications*, **438**: 697–702.
- Vermeulen, K., Van Bockstaele, D.R., dan Berneman, Z.N., 2005. Apoptosis: mechanisms and relevance in cancer. *Annals of Hematology*, **84**: 627–639.
- Vikram, R., Chou, W.C., Hung, S.-C., dan Shen, C.-Y., 2020. Tumorigenic and Metastatic Role of CD44–/low/CD24–/low Cells in Luminal Breast Cancer. *Cancers*, **12**: 1239.
- Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., dkk., 2015. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. *The Journal of Experimental Medicine*, **212**: 139–148.
- Wang, F., Yuan, C., Wu, H.-Z., Liu, B., dan Yang, Y.-F., 2021. Bioinformatics, Molecular Docking and Experiments In Vitro Analyze the Prognostic Value of CXC Chemokines in Breast Cancer. *Frontiers in Oncology*, **11**: .
- Wen, J., Wang, X., Pei, H., Xie, C., Qiu, N., Li, S., dkk., 2015. Anti-psoriatic effects of Honokiol through the inhibition of NF-κB and VEGFR-2 in animal model of K14-VEGF transgenic mouse. *Journal of Pharmacological Sciences*, **128**: 116–124.
- Witt, A.E., Lee, C.-W., Lee, T.I., Azzam, D.J., Wang, B., Caslini, C., dkk., 2017. Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. *Oncogene*, **36**: 1707–1720.
- Xia, X., 2017. Bioinformatics and Drug Discovery. *Current Topics in Medicinal Chemistry*, **17**: 1709–1726.
- Yi, X., Qi, M., Huang, M., Zhou, S., dan Xiong, J., 2022. Honokiol Inhibits HIF-1α-Mediated Glycolysis to Halt Breast Cancer Growth. *Frontiers in Pharmacology*, **13**: .
- Zhang, X., Li, F., Zheng, Y., Wang, X., Wang, K., Yu, Y., dkk., 2019. Propofol Reduced Mammosphere Formation of Breast Cancer Stem Cells via PD-L1/Nanog In Vitro. *Oxidative Medicine and Cellular Longevity*, **2019**: e9078209.
- Zhao, B., Erwin, A., dan Xue, B., 2018. How many differentially expressed genes: A perspective from the comparison of genotypic and phenotypic distances. *Genomics*, **110**: 67–73.